Evonik and Dr. Eckel to cooperate on phytogenics
- New component in the Gut Health Solutions portfolio from Evonik Animal Nutrition
- Phytogenics are important components of alternative solutions to antibiotic growth promoters
- Product from this partnership to be available in Europe in the first quarter of 2023
Essen, Germany. Evonik and Dr. Eckel Animal Nutrition have entered into a partnership effective January 1, 2023. This agreement will enable Evonik's Animal Nutrition business line to expand its product portfolio in the Gut Health Solutions area to include the phytogenics product class. Evonik plans to launch a first product from the partnership with Dr. Eckel in Europe in the first quarter of 2023.
Phytogenics are plant-based feed ingredients which play an important role in alternative solutions to antibiotic use in livestock farming. The use of antibiotic growth promoters in animal feed has been banned in the European Union since 2006.
"It often needs complex solutions to maintain health and productivity in the barn without antibiotics," says Gaetano Blanda, head of the Animal Nutrition business line at Evonik. “In combination with our existing Gut Health Solutions, phytogenics will help farmers achieve this goal.”
Evonik Gut Health Solutions focus primarily on stabilizing the gut health of animals through probiotics such as Ecobiol®, Fecinor®, and GutCare®. The partnership with Dr. Eckel, one of the most experienced and innovative suppliers in the field of phytogenics, will allow Evonik to address further animal health issues with selected products that expand Evonik’s portfolio.
Customized System Solutions consisting of several components and delivering sustainability benefits are part of the strategic core of Evonik's life science division Nutrition & Care, which includes the Animal Nutrition business line. With its products, services and knowhow, Evonik aims to help supply a growing world population with healthy animal protein in an efficient and sustainable way.
“As a dynamic company with a high pace in product development, we are able to create innovations in a comparatively short period of time,” says Dr. Antje Eckel, founder of Dr. Eckel Animal Nutrition. “With a strong partner like Evonik, we can allow selected products to access a much wider market in a short time. We are therefore very happy that together with Evonik we can open up new target groups and customers.”
Dr. Eckel Animal Nutrition is a family-run company with international operations. A broad knowledge of plant substances and their interactions as well as experience from almost three decades of work with innovative feeding solutions allows the company to develop phytogenics with specific benefits.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.56 billion in 2021 with about 5,300 employees.
About Dr. Eckel
Dr. Eckel Animal Nutrition is all about innovative feed additives made in Germany. The value-orientated family business was founded by Dr. Antje Eckel in Niederzissen / Germany in 1994. Today, Dr. Eckel is one of the world’s foremost companies in the sector with a specific focus on animal welfare, developing products that make animal nutrition more resource-efficient, climate-friendly and healthy. This is how Dr. Eckel contributes to sustainable global nutrition.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.